microshield 20 chlorhexidine concentrate
johnson & johnson (new zealand) limited - chlorhexidine gluconate 20%{relative} - topical solution - 20% w/v - active: chlorhexidine gluconate 20%{relative}
sodium chloride bp 20%
astrazeneca limited - sodium chloride 20%{relative} - solution for injection - 20% w/v - active: sodium chloride 20%{relative} excipient: hydrochloric acid water for injection
cavstat 20 rosuvastatin (as calcium) 20 mg tablets blister pack
accord healthcare pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; crospovidone; magnesium stearate; microcrystalline cellulose; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 20 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 20 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 20 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 20 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 20, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
cavstat 20 rosuvastatin (as calcium) 20 mg tablets bottle
accord healthcare pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; magnesium stearate; crospovidone; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 20 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 20 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 20 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 20 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 20, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
terbinafine 250mg tablets
ivax pharmaceuticals uk ltd - terbinafine hydrochloride - oral tablet - 250mg
caverject 20 µg inj. sol. (pwdr. + solv.) i.cavern. amp. pre-filled syr. vial
pfizer sa-nv - alprostadil 20 µg/ml - powder and solvent for solution for injection - 20 µg - alprostadil 20 µg - alprostadil
technescan dtpa 20.8 mg kit for radiopharm. prep. i.v. vial
curium belgium s.p.r.l.-b.v.b.a. - pentetreotide 20,8 mg - kit for radiopharmaceutical preparation - 20,8 mg - calcium trisodium diethylenetriaminepentaacetate (dtpa) 20.8 mg - technetium (99mtc) pentetic acid
tektrotyd 20 µg kit for radiopharm. prep. i.v. vial
narodowe centrum badan jadrowych pl - hynic-[d-phe1,tyr3-octreotide] trifluoroacetate 20 µg - kit for radiopharmaceutical preparation - 20 µg - hynic-[d-phe1,tyr3-octreotide] trifluoroacetate 20 µg - technetium (99mtc) hynic-octreotide
juzo liner dual stretch (20-30mmhg) below knee open toe lymphoedema garment short size i
20-30mmhg) below knee open toe lymphoedema garment short size i beige (juzo uk ltd -
juzo liner dual stretch (20-30mmhg) below knee open toe lymphoedema garment short size i
20-30mmhg) below knee open toe lymphoedema garment short size i black pepper (juzo uk ltd -